Director at Royalty Pharma (RPRX) receives 4,545 restricted stock units grant
Rhea-AI Filing Summary
Royalty Pharma plc director David C. Hodgson reported an acquisition of 4,545 restricted stock units linked to Class A ordinary shares as equity compensation. The award was granted under the company’s 2020 Independent Director Equity Incentive Plan and is scheduled to vest 100% on the earlier of one year from grant or the next annual shareholder meeting. The restricted stock units are held solely for the benefit of General Atlantic Service Company, L.P., and Hodgson disclaims beneficial ownership of the underlying shares. Following this grant, 37,873 Class A ordinary shares are reported as directly held.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 4,545 shares
Net Buy
1 txn
Insider
HODGSON DAVID C
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Class A Ordinary Shares | 4,545 | $0.00 | $0.00 |
Holdings After Transaction:
Class A Ordinary Shares — 37,873 shares (Direct)
Footnotes (1)
- F1. Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. The restricted stock units granted to the Reporting Person are held by him solely for the benefit of General Atlantic Service Company, L.P. The Reporting Person disclaims beneficial ownership of the restricted stock units in the underlying shares.
Key Figures
Restricted stock units granted: 4,545 units
Reported shares after grant: 37,873 Class A ordinary shares
Grant price per share: $0.0000 per share
+1 more
4 metrics
Restricted stock units granted
4,545 units
Award under 2020 Independent Director Equity Incentive Plan
Reported shares after grant
37,873 Class A ordinary shares
Holdings following the transaction
Grant price per share
$0.0000 per share
Reported transaction price on Form 4
Vesting schedule
100% cliff vesting
Earlier of one-year anniversary or next annual shareholder meeting
Key Terms
restricted stock units, 2020 Independent Director Equity Incentive Plan, beneficial ownership, annual meeting of the Issuer's shareholders
4 terms
restricted stock units financial
"Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2020 Independent Director Equity Incentive Plan financial
"under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan")"
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of the restricted stock units in the underlying shares."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Royalty Pharma (RPRX) report for David C. Hodgson?
Royalty Pharma reported that director David C. Hodgson received 4,545 restricted stock units as an equity grant. These units relate to Class A ordinary shares and were awarded at no cash cost under the 2020 Independent Director Equity Incentive Plan.
When do David C. Hodgson’s new Royalty Pharma (RPRX) restricted stock units vest?
The restricted stock units are scheduled to vest 100% on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting. Vesting also depends on the terms of the 2020 Independent Director Equity Incentive Plan and the related award agreement.
Who ultimately benefits from David C. Hodgson’s Royalty Pharma (RPRX) restricted stock units?
The filing states that Hodgson holds the restricted stock units solely for the benefit of General Atlantic Service Company, L.P. He disclaims beneficial ownership of the underlying shares, meaning economic benefits are attributed to that entity rather than to him personally.
Is David C. Hodgson’s Royalty Pharma (RPRX) transaction an open‑market purchase or sale?
No, the transaction is classified as a grant or award acquisition, not an open‑market trade. The restricted stock units were issued as compensation under the 2020 Independent Director Equity Incentive Plan at a reported price of $0.0000 per share.